5:38 PM
 | 
Oct 08, 2012
 |  BC Extra  |  Company News

Fibrocell in deal with Intrexon

Fibrocell Science Inc. (OTCBB:FCSC) announced a deal to use synthetic biology technologies from Intrexon Corp. (Blacksburg, Va.) to develop and commercialize next-generation autologous fibroblast and dermal cell therapies. The deal includes access to Intrexon's UltraVector technology and its platforms for...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >